Treatment success of Epidermal Growth Factor Receptor (EGFR) mutated Non-Small Cell Lung Cancer (NSCLC) with Tyrosine Kinase Inhibitors (TKIs) is hampered by treatment resistance development [1, 2]. Here, EGFR is linked to non-small cell lung carcinoma.